News stories about CareDx (NASDAQ:CDNA) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.6066882031223 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

CareDx (NASDAQ CDNA) traded up $0.03 during midday trading on Thursday, reaching $7.12. The company had a trading volume of 156,700 shares, compared to its average volume of 348,745. CareDx has a 52 week low of $0.76 and a 52 week high of $7.98. The company has a quick ratio of 0.35, a current ratio of 0.55 and a debt-to-equity ratio of -124.53.

CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02. The business had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $12.05 million. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. CareDx’s revenue was down 2.3% compared to the same quarter last year. sell-side analysts expect that CareDx will post -0.83 EPS for the current year.

Several equities research analysts recently commented on the company. HC Wainwright assumed coverage on CareDx in a report on Monday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Craig Hallum reiterated a “buy” rating and issued a $10.00 price objective (up from $4.00) on shares of CareDx in a report on Monday, October 9th. Raymond James Financial upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Wednesday, September 27th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $7.00 price objective (up from $3.00) on shares of CareDx in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $7.75.

In other CareDx news, COO Mitchell J. Nelles sold 10,948 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $7.17, for a total value of $78,497.16. Following the transaction, the chief operating officer now directly owns 84,225 shares of the company’s stock, valued at $603,893.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Neil Gagnon bought 10,642 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $42,568.00. The disclosure for this purchase can be found here. Company insiders own 5.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “CareDx (CDNA) Getting Somewhat Favorable Media Coverage, Report Shows” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/14/caredx-cdna-getting-somewhat-favorable-media-coverage-report-shows.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Stock Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related stocks with our FREE daily email newsletter.